Action AXSM AXSOME THERAPEUTICS, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Communiqués Axsome Therapeutics, Inc.

Actions

AXSM

US05464T1043

Marché Fermé - Nasdaq
Autres places de cotation
 22:00:00 16/07/2024 		Varia. 5j. Varia. 1 janv.
84,95 USD +2,60 % Graphique intraday de Axsome Therapeutics, Inc. +4,57 % +6,73 %
05/06 AXSOME THERAPEUTICS, INC. : RBC Capital Markets persiste à l'achat ZM
05/06 Axsome Therapeutics déclare avoir réglé le litige sur le brevet Sunosi avec Unichem Laboratories MT

Communiqués

Recherche
Voir les résultats
Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !
Inscription 100% Gratuite
Axsome Therapeutics to Report Second Quarter 2024 Financial Results on August 5
GL
Axsome therapeutics settles sunosi patent litigation with unichem laboratories
AQ
Axsome Therapeutics Settles Sunosi® (solriamfetol) Patent Litigation with Unichem Laboratories
GL
Axsome Therapeutics Joins the American Migraine Foundation to Highlight Unmet Treatment Needs During Migraine & Headache Awareness Month
GL
Axsome Therapeutics Joins the American Migraine Foundation to Highlight Unmet Treatment Needs During Migraine & Headache Awareness Month
AQ
Axsome Therapeutics Supports Alzheimer’s & Brain Awareness Month
GL
Axsome Therapeutics to Participate in Upcoming Investor Conferences
GL
Axsome Therapeutics to Participate in Upcoming Investor Conferences
AQ
Axsome Therapeutics Highlights Data on Solriamfetol Demonstrating Improvement in Cognitive Function in Patients with Obstructive Sleep Apnea or Narcolepsy at SLEEP 2024
GL
Axsome Therapeutics Presents Data from Multiple Programs at the 2024 American Society of Clinical Psychopharmacology Annual (ASCP) Meeting
GL
Axsome Therapeutics to Present at Upcoming Investor Conferences
GL
Axsome Therapeutics to Present at Upcoming Investor Conferences
AQ
Axsome: Q1 Earnings Snapshot
AQ
Axsome Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
GL
Axsome Therapeutics Recognizes May as Mental Health Awareness Month
GL
Axsome Therapeutics highlights innovative neuroscience portfolio at the american academy of neurology 2024 annual meeting
AQ
Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting
GL
Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting
AQ
Axsome Therapeutics to Report First Quarter 2024 Financial Results on May 6
GL
Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder
GL
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action AXSM
  4. Actualités Axsome Therapeutics, Inc.
  5. Communiqués